Home » Stocks » CNAT

Conatus Pharmaceuticals Inc. (CNAT)

May 27, 2020 - CNAT merged into HSTO
Stock Price: $0.556 USD 0.000 (0.00%)
Updated May 26, 2020 4:00 PM EDT
Market Cap 18.44M
Revenue (ttm) 14.69M
Net Income (ttm) -10.12M
Shares Out 33.17M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 26, 2020
Last Price $0.556
Previous Close $0.556
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.541 - 0.594
Day's Volume 1,696,913
52-Week Range 0.230 - 1.070

News

Hide News
GlobeNewsWire - 8 months ago

SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today...

GlobeNewsWire - 8 months ago

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today...

GlobeNewsWire - 8 months ago

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specif...

GlobeNewsWire - 9 months ago

SAN DIEGO, April 20, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced tod...

GlobeNewsWire - 9 months ago

SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced tod...

GlobeNewsWire - 11 months ago

Proposed Merger Creates Regenerative Medicine Company with Three Clinical-stage Product Candidates and Combined Company Capitalization Expected to Support Operations into 2021

Zacks Investment Research - 1 year ago

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Other stocks mentioned: AGN, CBAY, GLMD, ICPT, MDGL
GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an addition...

Zacks Investment Research - 1 year ago

Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 1 year ago

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

Zacks Investment Research - 1 year ago

Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined obj...

Benzinga - 1 year ago

Shares of micro-cap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) were sinking further into penny stock territory Tuesday after two announcements made Monday after the market close.

Zacks Investment Research - 1 year ago

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock ma...

Zacks Investment Research - 1 year ago

Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.

Zacks Investment Research - 1 year ago

Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.

Other stocks mentioned: AGN, GILD, ICPT, MRK, NVS
Zacks Investment Research - 1 year ago

Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.

Benzinga - 1 year ago

Shares of microcap biotech Conatus Pharmaceuticals Inc. are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate.

Zacks Investment Research - 1 year ago

Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.

Zacks Investment Research - 1 year ago

Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.

About CNAT

Conatus Pharmaceuticals, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing C... [Read more...]

Industry
Biotechnology
IPO Date
Jul 25, 2013
CEO
Steven J. Mento
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
CNAT
Full Company Profile